ViCentra Triples Insulin Pump Production, Eyeing European Expansion

UTRECHT, The Netherlands – May 28, 2026 – Dutch medical device firm ViCentra has announced a major manufacturing scale-up for its Kaleido insulin patch pump system, a move poised to significantly disrupt the European diabetes care market. By partnering with global contract manufacturer Phillips Medisize, the company is more than tripling its production capacity, enabling it to support over 17,000 users and aggressively expand its commercial footprint.

The collaboration marks the start of commercial-scale production for Kaleido's consumables, including its unique insulin cartridges and infusion sets. This operational milestone is not just about volume; it's a strategic maneuver designed to bolster the company's financial health by improving unit economics and gross margins, providing the fuel needed for sustained growth.

"This is a very significant and crucial operational milestone for ViCentra," said Tom Arnold, Chief Executive Officer of ViCentra. "Tripling capacity and improving margin performance allow ViCentra to bring Kaleido to more people living with diabetes, reliably and at scale, across additional markets."

A Strategic Leap in a Competitive Market

The timing of ViCentra's expansion is critical. The European insulin pump market, valued at over USD 2.1 billion in 2025, is projected to grow at a compound annual rate of over 15%, driven by rising diabetes prevalence and the rapid adoption of smarter, more connected devices. Within this burgeoning sector, patch pumps—discreet, wearable devices without long tubing—represent the fastest-growing and most lucrative segment.

ViCentra is now better positioned to capture a larger share of this market, particularly in key territories like Germany, the Netherlands, and France. Germany, the world's second-largest insulin pump market, is a primary target. With its advanced healthcare infrastructure and strong reimbursement policies, it represents a significant opportunity for a company now capable of delivering a reliable, high-volume supply.

The move places ViCentra in more direct competition with established industry giants like Insulet, Medtronic, and Tandem Diabetes Care. However, the company is betting on its product's unique design and user-centric features to carve out its niche. The increased supply will allow ViCentra to add thousands of new users through the second half of 2026, building on the momentum that saw its user base double to over 5,000 in the past year.

The Power of Partnership: Industrializing Innovation

Central to this expansion is the strategic alliance with Phillips Medisize, a Molex company and a leader in the contract development and manufacturing organization (CDMO) space. Phillips Medisize brings a wealth of experience in industrializing complex drug-delivery platforms, with a track record that includes components for insulin pens and continuous glucose monitoring (CGM) systems. Their expertise in high-volume precision molding, automated assembly, and stringent quality control provides the backbone for ViCentra's ambitious growth plans.

"ViCentra’s design‑led approach to wearable insulin delivery is exactly the type of innovation our global CDMO platform is built to industrialize," noted David Thoreson, Vice President of Global Operations at Phillips Medisize. This partnership allows ViCentra to leverage a validated, global-scale manufacturing infrastructure without the immense capital expenditure and lead time required to build it from scratch.

This CDMO model is becoming a blueprint for success in the medtech industry, enabling innovative but smaller companies to scale rapidly and compete with larger incumbents. By outsourcing production, ViCentra can focus on its core competencies: research, development, and commercialization, while ensuring a resilient and efficient supply chain. The resulting improvement in unit economics is expected to significantly strengthen the company's gross margins, freeing up capital for further innovation and market penetration.

Redefining Diabetes Care for Thousands

Beyond the business strategy, the scale-up promises a tangible impact on the lives of people with diabetes. The Kaleido system is marketed not just as a medical device, but as a piece of personal technology designed to integrate seamlessly into a user's life. It is the smallest and lightest pump in its class, offering a level of discretion that users praise. With ten customizable color options, it allows for self-expression, a stark contrast to the typically clinical look of medical hardware.

Patient feedback often highlights the system's comfort and flexibility. Its small size makes it easy to forget it's there, while its integration with Diabeloop’s DBLG2 hybrid closed-loop algorithm automates much of the difficult work of diabetes management. This algorithm, which connects the pump to a CGM, can predict glucose trends and adjust insulin delivery automatically, reducing the mental burden on the user and improving time in range.

The increased production capacity means that this life-changing technology will become accessible to a much larger patient population. Greater availability can help address unmet needs for a more discreet, flexible, and intelligent insulin delivery system, potentially improving treatment adherence and overall quality of life for thousands across Europe.

Sights Set on America: The Next Frontier

While Europe is the immediate focus, ViCentra's ambitions extend across the Atlantic. The company is actively preparing for entry into the highly competitive and lucrative U.S. market, a plan bolstered by its recent $98 million Series D financing round. Rather than introducing the current model, ViCentra is developing the Kaleido 2, a next-generation device designed to be even smaller and lighter, aiming to set a new standard for wearable insulin delivery.

ViCentra is targeting a U.S. launch in 2027, with plans to submit the Kaleido 2 system for FDA approval in late 2026. This timeline positions the company to challenge the market dominance of products like Insulet's Omnipod 5 directly. The combination of a next-generation device, a powerful algorithm, and the recently announced smartphone control functionality could create a compelling new option for American patients and providers.

With its manufacturing now operating at commercial scale, a strengthened balance sheet, and a clear roadmap for expansion, ViCentra has solidified its position as a formidable innovator in the global diabetes technology landscape. The company's presence at the upcoming American Diabetes Association (ADA) 86th Scientific Sessions signals its intent to engage with the international community as it transitions from a promising European startup to a global contender.